Navigation Links
Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years

Alexandria, VAResearchers report that just four months of hormonal therapy before and with standard external beam radiation therapy slowed cancer growth by as much as eight yearsespecially the development of bone metastasesand increased survival in older men with potentially aggressive prostate cancer. This neoadjuvant hormonal therapy may allow men most at risk of developing bone metastases avoid long-term hormonal therapy later on. Furthermore, the short-term hormonal therapy did not increase the risk of cardiovascular diseasea potential side effect of long-term hormonal therapy. The study is being published online January 2 in the Journal of Clinical Oncology (JCO).

Hormonal therapycalled androgen deprivation therapy (ADT)lowers levels of cancer-fueling testosterone in the blood. It is an important treatment option for men with prostate cancer that continues to progress despite initial treatment with surgery, radiation therapy, or chemotherapy, but has been associated with side effects such as bone loss, osteoporosis, depression and an increase in cardiovascular risk factors (including blood lipids, abdominal obesity and a syndrome associated with diabetes).

This study demonstrates that the benefits of short-term hormonal therapy for men receiving radiation therapy for prostate cancer far outweigh the risks, said lead author Mack Roach III, MD, professor and chair of radiation oncology and professor of urology at the University of California, San Francisco. While four months of hormonal therapy isnt enough to cause significant side effects, we found that it can delay the development of bone metastasis by as many as eight years, which is very significant.

Starting in 1987, Radiation Therapy Oncology Group researchers studied 224 men with high-risk prostate cancer who received ADT (goserelin and flutamide) before and concurrent with external beam radiation therapy, and 232 men with the disease who received radiation therapy alone. After 13 years of follow up, they found better 10-year disease-specific death rates (the rate of death from prostate cancer) for men who received ADT plus radiation (23 percent versus 36 percent of the radiation-only group), disease metastasis rates (35 percent versus 47 percent), disease-free survival (the percentage of men free of cancer at 10 years; 11 percent versus 3 percent) and biochemical failure rates (a rise in PSA levels; 65 percent versus 80 percent).

Among men who received neoadjuvant hormonal therapy, there was up to an eight-year delay in the time it took 40 percent of patients to develop bone metastases compared with men receiving radiation alone. Men who develop bone metastases often require long-term hormonal therapy, which can increase their risk for side effects. So by taking a little bit of hormonal therapy early, patients may avoid having to take a lot of it later, added Dr. Roach.

Fatal cardiac events occurred in 12 percent of patients in the ADT group compared with 9 percent of the radiation-only groupa difference that was not statistically significant.


Contact: Tiffany Reynolds
American Society of Clinical Oncology

Related medicine news :

1. portionpals(R) Sales Reach a Whopping 250,000 Units in 3 Months!
2. Experts propose cholesterol tests at 15 months of age
3. Florida Doctor Sentenced to 18 Months in Prison for Medicare Fraud
4. Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months
5. Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months
6. Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2007 Financial Results
7. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
8. Treadmill training helps Down syndrome babies walk months earlier
9. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007
10. MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007
11. Chindex International, Inc. Announces Results for the Quarter and Six Months Ended September 30, 2007
Post Your Comments:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: